<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 23, 1997
REGISTRATION NO. 33-72124
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST EFFECTIVE
AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ISIS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware 33-0336973
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
2292 Faraday Avenue
Carlsbad, California 92008
(760) 931-9200
(Address, including zip code, and telephone number, include area code, of
Registrant's principal executive offices)
B. Lynne Parshall, Esq.
Executive Vice President and Chief Financial Officer
ISIS PHARMACEUTICALS, INC.
2292 Faraday Avenue
Carlsbad, California 92008
(760) 931-9200
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
D. Bradley Peck, Esq.
COOLEY GODWARD LLP
4365 Executive Drive
San Diego, CA 92121
(619) 550-6000
================================================================================
<PAGE> 2
This Post-Effective Amendment No. 1 is being filed to deregister
1,098,684 shares of Common Stock (the "Shares") of Isis Pharmaceuticals, Inc.
covered by the Form S-3 Registration Statement No. 33-72124 (the "Registration
Statement"). The Shares are no longer being offered by the holders thereof in
registered resale transactions described in the prospectus filed as part of the
Registration Statement.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has duly caused this Post-Effective Amendment No. 1
to the Registration Statement to be signed on its behalf by the undersigned
thereunto duly authorized, in the city of Carlsbad, County of San Diego, State
of California, on the 22nd day of July 1997.
ISIS PHARMACEUTICALS, INC.
By: /s/ B. LYNNE PARSHALL
------------------------------------
B. Lynne Parshall
Executive Vice President and
Chief Financial Officer
Pursuant to the requirements of the Securities Act of 1933, this
Post-Effective Amendment No. 1 to the Registration Statement has been signed
below by the following persons in the capacities indicated and on the dates
indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
* Chairman of the Board and Chief July 22, 1997
- ---------------------------------- Executive Officer (Principal
Stanley T. Crooke, M.D., Ph.D executive officer)
/s/ B. LYNNE PARSHALL Executive Vice President and July 22, 1997
- ---------------------------------- Chief Financial Officer
B. Lynne Parshall (Principal financial and
accounting officer)
* President, Chief Operating July 22, 1997
- ---------------------------------- Officer and Director
Daniel L. Kisner, M.D.
* Director July 22, 1997
- ----------------------------------
Burkhard Blank
* Director July 22, 1997
- ----------------------------------
Christopher F.O. Gabrieli
* Director July 22, 1997
- ----------------------------------
Alan C. Mendelson
* Director July 22, 1997
- ----------------------------------
William R. Miller
* Director July 22, 1997
- ----------------------------------
Mark B. Skaletsky
* Director July 22, 1997
- ----------------------------------
Larry Soll, Ph.D.
* Director July 22, 1997
- ----------------------------------
Joseph H. Wender
</TABLE>
*By: /s/ B. LYNNE PARSHALL
------------------------------
B. Lynne Parshall, Attorney-
in-Fact
3
